Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ranbaxy

- PMLiVE

FDA guidance clears path for Advair generics

Offers simplified process for potential copies of GSK’s asthma and COPD drug

- PMLiVE

Lundbeck still ‘appalled’ by EC’s €94m anti-competition fine

Will appeal, but doesn't expect a quick decision

- PMLiVE

Indian generics companies poised for branded push

Report predicts manufacturing innovation will be harnessed for new patented products

- PMLiVE

Lundbeck losses deepen on EU fine

Pay-for-delay penalty contributes to operating loss of 506m Danish krone

- PMLiVE

Merck profit slides as generics continue to bite

Singulair, Maxalt, Cozaar and Clarinex sales all affected

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

European Commission hails progress on paediatric medicines

Says improvements made on both safety and research in Europe

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

- PMLiVE

Lundbeck to cut 50 jobs in Europe

Part of restructuring operations to cope with patent loss for Cipralex/ Lexapro

EU flag

EC fines pharma companies €146m for generic Celexa delay

Lundbeck, Alpharma, Merck KGaA, Generics UK, Arrow and Ranbaxy all hit

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links